Search results
We’re on the road with a new approach to clinical trials—one that expands access to cutting-edge medicines and treatments. Lilly is a medicine company turning science into healing to make life better for people around the world.
The company was founded by Colonel Eli Lilly, a pharmaceutical chemist and Union Army veteran of the American Civil War. Lilly served as the company president until his death in 1898. [18]
We’re a medicine company turning science into healing to make life better for people around the world. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges.
Find the latest Eli Lilly and Company (LLY) stock quote, history, news and other vital information to help you with your stock trading and investing.
Jun 25, 2024 · The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
Jul 11, 2024 · We believe that Eli Lilly stock (NYSE: LLY) is currently a better pick than its industry peer – Pfizer stock, given its better prospects.
Jul 2, 2024 · The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
Mar 31, 2024 · Lilly at a Glance. A heritage 148 years strong: company founded on May 10, 1876. Headquarters located in Indianapolis, Indiana, U.S.A. More than 44,000 employees worldwide. Approximately 10,000 employees engaged in research and development. Clinical research conducted in more than 55 countries.
Jul 8, 2024 · INDIANAPOLIS and WALTHAM, Mass., July 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases.
Apr 30, 2024 · Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum. Revenue in Q1 2024 increased 26%, driven by Mounjaro, Zepbound, Verzenio and Jardiance. Pipeline progress included positive results from two Phase 3 trials of tirzepatide for obstructive sleep apnea ...
